Adenosine, a neuromodulator of the CNS, activates inhibitory-A 1 receptors and facilitatory-A 2A receptors; its synaptic levels are controlled by the activity of bi-directional equilibrative nucleoside transporters. To study the relationship between the extracellular formation/inactivation of adenosine and the activation of adenosine receptors, we investigated how A 1 and A 2A receptor activation modifies adenosine transport in hippocampal synaptosomes. The A 2A receptor agonist, CGS 21680 (30 nM), facilitated adenosine uptake through a PKCdependent mechanism, but A 1 receptor activation had no effect. CGS 21680 (30 nM) also increased depolarization-induced release of adenosine. Both effects were prevented by A 2A receptor blockade. A 2A receptor-mediated enhancement of adenosine transport system is important for formatting adenosine neuromodulation according to the stimulation frequency, as: (1) 
Adenosine is a modulator that exerts its action through four types of metabotropic receptors -A 1 , A 2A , A 2B and A 3 (Fredholm et al. 2001) . In particular, the neuromodulatory role of adenosine depends mostly on a balanced activation of inhibitory A 1 receptors and facilitatory A 2A receptors (see Sebastião and Ribeiro 2000) . There are two main sources of extracellular adenosine in the nervous system: adenosine release through bi-directional equilibrative nucleoside transporters (ENTs) and extracellular conversion of adenine nucleotides into adenosine by ecto-nucleotidases (for review see Latini and Pedata 2001) . Whereas ecto-nucleotidases can only form adenosine, nucleoside transporters fulfil a dual 6 -cyclopentyladenosine; dbcAMP, N 6 ,2¢-o-dibutyryladenosine-3¢,5¢-cyclic monophosphate sodium salt; DMSO, dimethylsulfoxide; DPCPX, 1,3-dipropyl,8-cyclopentylxanthine; ENT, equilibrative nucleoside transporters; GF-109203X, 2-[1- (3-dimethylaminopropyl) indol-3-yl]-3-(indol-3-yl) maleimide; H-89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride; HC-3, hemicholinium-3; HFS, highfrequency stimulation; HPLC, high-performance liquid chromatography; LFS, low-frequency stimulation; NBTI, S-(p-nitrobenzyl)-6-thioinosine; PDD, phorbol-12,13-didecanoate; SCH 58261, 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3- role, because blockade of adenosine transport can inhibit either adenosine release or adenosine uptake in the hippocampus, depending upon its intra-and extracellular levels (Gu et al. 1995) .
The activity of ENTs is controlled by G proteins (Sweeney 1996) and protein kinases (Sen et al. 1999) . Adenosine receptors, which are coupled to G proteins and protein kinase-dependent transducing systems, appear therefore to be good candidates to modify the levels of their endogenous ligand, adenosine. It has been shown that A 2 receptor activation can increase adenosine uptake in chromaffin cells (Delicado et al. 1990) , an issue that remains to be confirmed in neurones. This control of the levels of extracellular adenosine by adenosine A 2 receptors might be particularly important in brain areas such as the hippocampus under highfrequency neuronal firing, which favours the activation of adenosine receptors of the A 2A subtype (Cunha et al. 1996a) , as well as a predominant formation of extracellular adenosine through the ecto-nucleotidase pathway (Cunha et al. 1996b) .
Thus, we now directly tested if the activation of adenosine A 2A receptors could control the release and uptake of adenosine through nucleoside transporters in hippocampal preparations. This was tested in nerve terminals where ENTs play an important role in the metabolism of adenosine (e.g. Gu et al. 1995) . Because it was previously shown that the evoked release of acetylcholine (ACh) from rat hippocampal slices is under the control of endogenous extracellular adenosine operating mainly A 1 receptors (Jackisch et al. 1984) , but also A 2A receptors (Cunha et al. 1994) , the modulation of electrically evoked [ 3 H]ACh release by tonic A 1 receptor activation was subsequently used in the present work as a 'model' to evaluate how the A 2A receptor-mediated enhancement of nucleoside transporters could affect tonic neuromodulation by endogenous adenosine.
Materials and methods

Materials
,2¢-o-dibutyryladenosine-3¢,5¢-cyclic monophosphate sodium salt (dbcAMP), N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-89), phorbol-12,13-didecanoate (PDD) and adenosine were from Sigma (St Louis, MO, USA). 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo [1,5-c] (v/ v) . The following stock solutions were prepared in DMSO: CGS 21680 (5 mM), SCH 58261 (5 mM), CPA (5 mM), adenosine (100 mM), dipyridamol (2.5 mM), NBTI (10 mM), PDD (5 mM), GF-109203X (5 mM) and H-89 (5 mM). HC-3 (10 mM) and dbcAMP (10 mM) were prepared in water. Aliquots of all stock solutions were kept frozen at )20°C until used.
Preparation of CA3 subslices and synaptosomes from rat hippocampus The experiments were performed on Wistar rats (6-8 weeks old) from Harlan Interfauna Iberica, SL (Barcelona, Spain). The animals were handled according to the European Community guidelines and Portuguese law on Animal Care and were anaesthetized with halothane before decapitation. The hippocampus was dissected free within ice-cold Krebs' solution of the following composition: 124 mM NaCl, 3 mM KCl, 1.25 mM NaH 2 PO 4 , 1 mM MgSO 4 , 2 mM CaCl 2 , 26 mM NaHCO 3 and 10 mM glucose, pH 7.4.
When preparing hippocampal slices, the hippocampi were transversely cut 400 lm thick, the CA3 subslices manually dissected and allowed to recover for 1 h in gassed Krebs solution (95% O 2 and 5% CO 2 ) kept at room temperature (20-22°C).
The synaptosomal P2 fraction and purified nerve terminals (synaptosomes) were isolated as previously (e.g. Cunha et al. 2000) .
[ 3 H]Adenosine uptake assay Synaptosomes were resuspended in 1 mL of Krebs/HEPES solution with the following composition: NaCl 124 mM, KCl 3 mM, NaH 2 PO 4 1.25 mM, MgSO 4 1 mM, CaCl 2 2 mM, HEPES 26 mM, glucose 10 mM, pH 7.4) and equilibrated at 37°C. All adenosine transport assays were conducted at 37°C in a total volume of 300 lL, containing 150-200 lg of protein (see Cunha et al. 2000) . Transport was initiated by addition of 1 lM [ 3 H]adenosine, added at least 10 min after exposing synaptosomes to the tested drugs, and was terminated 15 s after initiating its uptake by the addition of 5 mL of an ice-cold transport inhibitor mixture composed by dipyridamol (20 lM), NBTI (10 lM) and adenosine (1 mM), in Krebs/H followed by low-pressure filtration through 0.45-lm filters (Millipore LCWP-047, Millipore Corporation, Bedford, MA, USA) loaded in a Millipore holder. The reaction tube was washed off with further 5 mL of the same solution. The filters were analysed by liquid scintillation counting for determination of tritium retained by synaptosomes after addition of 5 mL of scintillation cocktail (Optiphase Hi-Safe 2, Perkin-Elmer, Foster City, CA, USA). Adenosine transport was calculated as the difference between the total amount of adenosine taken up by synaptosomes and the nonspecific component of [ 
Adenosine release experiments
Because considerable amounts of protein are required for these assays, the P2 synaptosomal fraction was used. Perfusion chambers (90 lL) fitted with Whatman (Brentford, Middlesex, U.K.) GF/C filters were loaded with the synaptosomal fraction and a period of 45 min was allowed for equilibrium, before starting sample collection. Perfusion was at 0.6 mL/min with a 95% O 2 /5% CO 2 gassed Krebs solution at 32°C throughout the experiment. Drugs were added 10 min prior to starting sample collection, and were present onwards. Synaptosomes were stimulated from minute 6 to minute 11 with a high-K + (28 mM) solution. Each individual experiment comprised a control chamber and one different chamber for each drug condition. The amount of adenosine in each collected sample (3 min) was assessed after derivatization to N 6 -ethenoadenosine, and then quantified by high-performance liquid chromatography [HPLC; 100 mM K 2 HPO 4 in 15% (v/v) methanol/water, pH 6.5, 1.75 mL/ min flow rate] with fluorescence detection (see Zhang et al. 1991 H]choline (12.3 lCi/mL, 0.15 lM) for 30 min at 32°C and washout, the subslices were placed in 100 lL Perspex chambers (three subslices per chamber) and superfused with gassed Krebs solution at 32°C (flow rate of 0.6 mL/min). From this moment onwards hemicholinium-3 (10 lM) was present in all solutions used. A washout period of 45-60 min was allowed before starting sample (3 min) collection. The preparations were then stimulated at min 6 (S1) and at min 36 (S2) with supramaximal square-wave pulses (1 ms, with an amplitude of approximately 15 V). Stimuli were delivered either with low-frequency (LFS, 2 Hz for 2 min; total number of pulses: 240) or with high-frequency (HFS, 50 Hz). HFS paradigm consisted of four bursts (1.2 s each) of 60 pulses (total number of pulses: 240), applied with 200 ms interburst periods, except otherwise indicated.
Four perfusion chambers were used per experiment, two for controls (absence of drugs, or same drugs during S1 and S2) and two for test conditions (test drug before S2). When the effects of either the A 1 antagonist, DPCPX (250 nM), or the A 1 agonist, CPA (300 nM), were investigated, these test drugs were added to the perfusion medium 21 min before S2, i.e. 15 min after starting sample collection, and remained in the superfused solution up to the end of the experiment. The effects of each of these test drugs on the evoked release of [ 3 H]ACh were expressed by changes of the ratios between the evoked release in S2 (in the presence of the drug) and the evoked release in S1 (in the absence of drugs; S2/S1 ratio), by comparison with the S2/S1 ratios obtained in control conditions in the same experiment (i.e. in the absence of drugs). When evaluating the effects of DPCPX (250 nM) in the presence of the ENT inhibitor, NBTI (10 lM), or the A 2A receptor antagonist, SCH 58261 (250 nM), these drugs were applied 15 min before starting sample collection and were present in all superfused solutions from that moment onwards; because both stimulation periods were performed under the effects of those drugs, the S2/S1 ratios remained virtually unaffected. In these experiments, DPCPX (250 nM) was added to the superfused conditions 15 min before S2, as before, and its effect expressed by changes in the S2/S1 ratio, as compared it with the S2/S1 ratios obtained in control conditions in the same experiments (i.e. in the presence of either NBTI or SCH 58261).
At the end of the experiments the slices were homogenized (sonicated in 500 lL of 3 M perchloric acid and 20% Triton X-100) and sampled. All samples were analysed by scintillation counting. The evoked release was calculated by integration of the area of the peak on subtraction of the estimated basal tritium outflow from the total outflow due to electrical stimulation. Field-electrically evoked tritium outflow from hippocampal slices loaded with [ 
Statistical analyses
Data are presented as the mean results ± SEM from n experiments. When comparing two-groups of results, statistical significance was assessed using Student's t-test. When doing multiple comparisons, statistical significance was assessed by one-way ANOVA followed by the Bonferroni correction, using GraphPad Software (Prism, version 4.02 for Windows). Values of p < 0.05 were considered statistically significant.
Results
Activation of A 2A receptor enhances adenosine uptake
In the experiments evaluating adenosine uptake, [
3 H]adenosine was applied at a concentration near the nucleoside transporters K m value for adenosine, 1 lM, as first calculated by Bender et al. (1981) for cortical synaptosomes, and found to be similar for nucleoside transporters in the hippocampus (Cunha et al. 2000) . Thus, we compared the ability of hippocampal nerve terminals to take up adenosine at a concentration of 1 lM in the absence and in the presence of the selective A 2A receptor agonist CGS 21680. In a control situation, synaptosomes incorporated 0.27 ± 0.06 pmol of [ 3 H]adenosine per mg of protein. As Fig. 1 shows, CGS 21680 (30 nM) significantly (p < 0.05) increased the uptake of adenosine by 66 ± 17% (n ¼ 7). This CGS 21680-induced enhancement of adenosine uptake was totally prevented by the selective A 2A receptor antagonist, SCH 58261 (250 nM, n ¼ 7), which by itself did not appreciably modify [ 3 H]adenosine uptake. Activation of A 1 receptors with the selective A 1 receptor agonist, CPA (100 nM), failed to modify (n ¼ 7, p > 0.05) the uptake of [ messengers were involved in the A 2A receptor-mediated facilitation of adenosine uptake by studying the effect of CGS 21680 in the presence and in the absence of protein kinases inhibitors. We also compared the effect of CGS 21680 on [ 3 H]adenosine uptake with those of the cAMP analogue, dbcAMP (0.1 mM) and the PKC activator, PDD (250 nM; Castagna et al. 1982) . In this new set of experiments, synaptosomes took up 0.30 ± 0.06 pmol of 
Activation of A 2A receptor enhances adenosine release
The observation that the activation of A 2A receptors enhanced the uptake of adenosine does not allow to discriminate between the possibilities that A 2A receptor activation was either directly interfering with the activity of nucleoside transporters or indirectly conditioning their function by modifying the gradient of adenosine across the plasma membrane, i.e. changing intrasynaptosomal metabolism (see e.g. Hammer et al. 2001) . To check the first possibility we took advantage of the bi-directionality of the nucleoside transporters, and evaluated if the activation of A 2A receptors would modulate the release of adenosine from hippocampal nerve terminals. Figure 3 shows that CGS 21680 (30 nM) significantly (n ¼ 6, p < 0.05) increased by 91 ± 12% the extracellular accumulation of adenosine evoked by a pulse of high potassium, when compared to the same depolarizing conditions in the absence of CGS 21680. This effect was totally prevented by the selective A 2A receptor antagonist, ZM 241385 (50 nM).
Under the experimental conditions used, the evokedrelease of adenosine was in great part due to the activity of ENTs as the inhibitors of nucleoside transporters, NBTI (10 lM) plus dipyridamol (20 lM), reduced the evoked release of adenosine by 63 ± 9% (n ¼ 3, p < 0.05). Furthermore, the ability of A 2A receptors to facilitate the evoked release of adenosine from nerve terminals was also significantly attenuated (69 ± 18%, n ¼ 4, p < 0.05) in the presence of dipyridamol (20 lM) plus NBTI (10 lM), indicating that the facilitatory effect of CGS 21680 mostly depends on the activity of ENTs. (Correia-de-Sa et al. 1996) , and any influence of A 2A receptor activation upon the transport of adenosine across the plasma membrane should result in differences in the modulation of evoked [ 3 H]ACh release by endogenous adenosine. We performed these experiments in the CA3 area of the hippocampus because it was previously shown that, in this area, endogenous adenosine tonically activates both inhibitory-A 1 and facilitatory-A 2A receptors, with the overall effect being a tonic inhibition of [ 3 H]ACh release (Cunha et al. 1994) .
The relative amount of tritium released after depolarizing the subslices with either LFS (2 Hz, 2 min) or HFS (four bursts of 60 pulses at 50 Hz, with an interburst interval of 200 ms) was similar for both stimulation paradigms (Fig. 4a) . As expected, the selective A 1 receptor antagonist, DPCPX (250 nM; Cunha et al. 1994) , facilitated the release of [
3 H]ACh triggered by LFS (14.5 ± 2.8% increase; n ¼ 4, p < 0.05). In contrast, when CA3 hippocampal subslices were stimulated with the HFS paradigm, DPCPX (250 nM) failed significantly (n ¼ 5, p > 0.05) to modify the evoked release of [ 3 H]ACh (Fig. 4b) . To avoid the feed-forward inhibition of ecto-5¢-nucleotidase by ATP released during stimulation (e.g. James and Richardson 1993), which could occlude endogenous neuromodulation by adenosine during HFS trains, we performed experiments in which the CA3 hippocampal subslices were also stimulated at 50 Hz (five bursts of 150 pulses for 3 s; total number of pulses 240, as for the LFS) but with longer (17 s) interburst intervals (HFS L ). This protocol might temporally bypass inhibition of ecto-5¢-nucleotidase and create conditions for the formation of adenosine from released adenine nucleotides (see Correiade-Sá et al. 1996) . However, under this HFS L protocol, DPCPX (250 nM) also failed to modify (n ¼ 5, p > 0.05) the evoked release of [ Our first working hypothesis predicted that HFS would trigger a preferential formation of ATP-derived adenosine, potentiating A 2A receptor activation and enhancing the uptake activity of nucleoside transporters, thus largely decreasing A 1 receptor tonic activation. Some readily testable strings of this hypothesis were considered: (i) the blockade of nucleoside transporters would allow a greater accumulation of adenosine, which would now be able to activate A 1 receptors; (ii) the blockade of A 2A receptors would prevent the enhancement of nucleoside transporters efficiency and hence adenosine would accumulate and activate A 1 receptors. As predicted, upon blockade of ENTs with NBTI (10 lM, present in S1 and S2), DPCPX (250 nM, added before S2) was now able to increase by 15.6 ± 0.9% (n ¼ 5, p < 0.05) the evoked release of in marked contrast with the lack of effect of DPCPX (250 nM) in the absence of the adenosine transport inhibitor (Fig. 5) . Using the LFS paradigm, no significant (n ¼ 3, p > 0.05) differences in the DPCPX-induced facilitation of (Fig. 6 ). SCH 58261 (250 nM) also tended to increase the effects of DPCPX (250 nM) under LFS stimulation but this did not reach statistical significance (n ¼ 4, p > 0.05; Fig. 5) .
From the results shown in Figs 5 and 6 it also emerged that the action of DPCPX upon HFS and LFS is similar, providing that adenosine transporters are inhibited (Fig. 5,  2nd and 4th bar) or A 2A receptors blocked (Fig. 6, 2nd and 4th bar).
Discussion
The main finding of the present work was that A 2A receptors enhance the activity of nucleoside transporters in rat hippocampal nerve terminals. Thus, activation of A 2A receptors with their selective agonist, CGS 21680, facilitated the uptake of adenosine and enhanced the evoked release of adenosine, which points to a direct effect of A 2A receptors on nucleoside transporters, rather than an indirect action resulting from a modification of the adenosine gradient of concentrations across the plasma membrane (i.e. metabolic (-) or presence (+) of NBTI (10 lM) is indicated below each bar. NBTI (10 lM) was added before starting sample collection and was present thereafter during S1 and S2; DPCPX (250 nM) was added 15 min before S2. The action of DPCPX in the presence of NBTI (+) was calculated by comparing the S2/S1 ratio obtained in the same experiments in parallel chambers where only NBTI was added. The effect of DPCPX in the absence of NBTI (-) was calculated by taking as control the S2/S1 ratios obtained in the same experiments in parallel chambers with no added drugs. Note that the presence of NBTI (10 lM) enhanced the facilitatory effect of DPCPX (250 nM Fractional release is the relative amount of tritium present in each collected sample in comparison to the total amount of tritium present in the tissue at the time of sample collection. The stimulation periods, S1 and S2, were applied at min 6 (S1) and min 36 (S2). Note that the relative amount of tritium released after stimulation is similar for both stimulation paradigms. The S2/S 1 ratios obtained under HFS (1.15 ± 0.02, n ¼ 8) and LFS (1.12 ± 0.04, n ¼ 7) were also not significantly different (p > 0.05). Each point is mean ± SEM (b) Comparison of the facilitatory effect of the selective A 1 receptor antagonist, DPCPX (250 nM), on the field electrically evoked release of [ 3 H]ACh from CA3 hippocampal slices under LFS and HFS, as indicated below each bar. DPCPX (250 nM) application 15 min before S2 significantly increased the S2/S1 ratios under LFS (n ¼ 4, p < 0.05), but not under HFS (n ¼ 5, p > 0.05). As indicated (*p < 0.05), the effects of DPCPX under both stimulation paradigms were statistically different. Each bar is mean ± SEM. effect). Furthermore, as for the exogenously added A 2A receptor agonist, endogenous adenosine released upon HFS was able to activate A 2A receptors and enhance the activity of nucleoside transporters. The main consequence of this A 2A receptor-mediated enhancement of the activity of nucleoside transporters was the marked reduction of the tonic activation of inhibitory A 1 receptors upon high-frequency firing. This modulatory action of A 2A receptors on the activity of the adenosine transporters constitutes a clear demonstration that a neuromodulatory receptor is able to control the extracellular levels of its endogenous ligand and, hence, to influence its ability to control neurotransmitter release.
Nucleoside transporters are a family of membrane proteins with different pharmacological and kinetic properties that have in common their ability to transport nucleosides, namely adenosine, through the plasma membrane (reviewed in Cabrita et al. 2002) . Two main groups of nucleoside transporters have been identified: (i) concentrative transporters (CNTs; Gray et al. 2004) , which use sodium gradient to transport nucleosides against their concentration gradient and (ii) equilibrative bi-directional transporters (ENTs; Baldwin et al. 2004) . Low nanomolar concentrations (50 nM) of NBTI block the ENT1 subtype (also called es from equilibrative-sensitive), whereas blockade of the equilibrative insensitive (ei) ENT2 subtype is attained with micromolar (10 lM) concentrations of NBTI or dipyridamole (Archer et al. 2004) . Therefore, in our experimental conditions, the NBTI (10 lM)-sensitive adenosine uptake and release might occur through ENTs, either of the ENT1 or ENT2 subtypes, which are widely expressed in the brain, including in hippocampal neurones (Anderson et al. 1999a (Anderson et al. , 1999b and play the major role in controlling the extracellular levels of adenosine in neuronal cells. Evidence for moderate levels of CNT2 transcripts in adult rat brain including hippocampal neurones has been recently reported (Guillén-Gó mez et al. 2004) . It was also recently shown that the activity of CNT2 in non-excitable cells is enhanced by activation of A 1 receptors (Duflot et al. 2004) , which in our experimental conditions did not influence adenosine uptake by nerve terminals. The relative contribution, if any, of CNTs for adenosine transport in the hippocampus and how they are regulated by selective activation of adenosine receptors remains to be investigated and is outside the scope of the present work.
In spite of the evidence available to support a predominant role of ENTs in controlling the levels of extracellular adenosine in the nervous system, little is known about the modulation of the activity of ENTs. They are known to display a peculiar mnemonic-like activity (Casillas et al. 1993) and some evidence has been gathered indicating that their activity can be modulated by G proteins (Sweeney 1996) and protein kinases (Sen et al. 1999) . A 2A receptors are coupled to several G proteins and their activation influences at least the activities of two types of protein kinases, PKA and PKC. The findings that a PKC inhibitor, but not a PKA inhibitor, prevents the enhancement of adenosine transport induced by the A 2A receptor agonist, and that PKC activators per se influence adenosine transport in a similar way to CGS 21680, suggest that A 2A receptors control ENTs activity in a PKC-dependent manner.
The function of A 2A receptors in the hippocampus still remains controversial. In fact, the most evident role of endogenous extracellular adenosine in the hippocampus is an inhibition of synaptic transmission and neuronal excitability through the activation of the more abundant A 1 receptors (reviewed in Dunwiddie and Masino 2001) . However, the activation of A 2A receptors causes a discrete facilitation of synaptic transmission and neurotransmitter release, which is in part due to their ability to decrease A 1 receptor function (Lopes et al. 2002) . Also, A 2A receptors effectively control, in a permissive manner, the action of other neuromodulatory systems, leading to the proposal that A 2A receptors are mostly devoted to the fine-tuning of other neuromodulatory systems, rather than to directly controlling the release of neurotransmitters (Sebastião and Ribeiro 2000) . The current observation that A 2A receptors can also control the activity of ENTs further widens the scope of the potential impact of A 2A receptors in controlling the function of nerve terminals and challenges further investigations on other cell types in the brain that also possess A 2A receptors and ENTs, such as microglia (e.g. Küst et al. 1999; Hong et al. 2000) and astrocytes (e.g. Gu et al. 1996; Nishizaki et al. 2002) . Interestingly, the fine-tuning neuromodulatory actions mediated by A 2A receptor activation may involve the PKA/cAMP transducing system (e.g. Dió genes et al. 2004) but in some cases, as observed in the present work, may be independent of PKA and involve PKC (e.g. Lopes et al. 2002) . One important aspect in the realm of the physiological function of the observed modulation of ENTs activity by A 2A receptor activation is to understand if this will lead to a greater ability to release or remove synaptic adenosine. In fact, the seminal work of Geiger's group has clearly established the bi-directional activity of ENTs (see Gu et al. 1995) . When studying the release of adenosine from nerve terminals, inhibition of ENTs decreases the evoked release of adenosine (MacDonald and White 1985) , which indicates that, at least in these structures, ENTs contribute to the release of the nucleoside. Nonetheless, in more integrated preparations, such as electrically stimulated brain slices, it is most commonly observed that inhibitors of ENTs actually enhance the extracellular levels of adenosine (reviewed in Latini and Pedata 2001) , implying that the net result of ENT activity is to take up the nucleoside. Indeed, extracellular adenosine concentrations are usually higher than the intracellular ones because (i) neuronal stimulation leads to the release of adenine nucleotides that are converted to adenosine through the ecto-nucleotidase pathway (see Zimmermann 2000) and (ii) cytoplasmatic adenosine is quickly converted into AMP, through adenosine kinase (see e.g. Latini and Pedata 2001) , which may further favour the uptake of adenosine in order to re-equilibrate its gradient across the cell membrane. In accordance with the predominant role of ENTs to take up, rather than to release, adenosine in hippocampal preparations, one should expect that the A 2A receptor-mediated enhancement of the activity of ENTs would result in an enhancement of the uptake of extracellular adenosine and therefore, to a lower degree of tonic activation of the predominant adenosine receptors in the hippocampus, the A 1 inhibitory receptors. This was directly confirmed when comparing adenosine modulation of the electrically evoked release of ACh at high and low frequencies of stimulation.
The different patterns of adenosine modulation of AChevoked release according to the frequency of stimulation observed in the present work, may be combined with what is known about frequency-dependency of adenosine metabolism, as summarized in Fig. 7 . Upon HFS of hippocampal preparations, there is a predominant release of ATP and a predominant formation of adenosine from this released ATP (Cunha et al. 1996b) . Thus, under conditions of HFS it is expected that the gradient of adenosine concentrations across the plasma membrane will direct ENTs to take up adenosine. Also, it was previously shown that ATP-derived adenosine preferentially activates A 2A receptors (Cunha et al. 1996a) and, consequently, stimulation at high frequencies leads to a preferential activation of A 2A receptors. This is consistent with the hypothesis displayed in Fig. 7(b) that the greater activation of A 2A receptors by the increased formation of ATP-derived adenosine upon HFS might be increasing the activity of nucleoside transporters to avoid a spread of Model for the role of A 2A receptors in the modulation of synaptic adenosine levels. Upon low frequency stimulation (a), the build-up of extracellular adenosine is moderate and dependent on both ENT's activity and the ecto-5¢-nucleotidase (5¢-N) pathway derived adenosine. In these conditions adenosine reaches A 1 receptors in the active zone, resulting in a tonic inhibitory effect of neurotransmitter (NT) release. During high frequency stimulation (b) the increased formation of ATP-derived adenosine leads to a greater activation of A 2A receptors that in turn increase the activity of nucleoside transporters to avoid a spread of extracellular adenosine, limiting its availability to activate A 1 receptors. extracellular adenosine sufficient to activate A 1 receptors. This means that there is a tight interplay between the extracellular metabolism of adenosine and the activation of adenosine receptors in the synaptic cleft to define the outcome of adenosine neuromodulation. Accordingly, under low-frequency firing there is a moderate build-up of extracellular adenosine that reach A 1 receptors because of the moderate activity of ENTs to take up adenosine (Fig. 7a) . This hypothetical scenario, which successfully explains the data observed, takes into account the tight association between ecto-nucleotidases, namely ecto-5¢-nucleotidase, and A 2A receptors (Cunha et al. 1996a; Napieralski et al. 2003) and re-enforces the likely close association of A 1 receptors with ENTs. However, it is obviously based on some key concepts that await experimental confirmation. Namely, it assumes that the different players involved in adenosine neuromodulation have a highly organized localization in a synapse and that there is a gradient of synaptic adenosine concentrations that varies according to the site of formation and removal of adenosine from the synapse.
In conclusion, the present work indicates that synaptic A 2A receptors in the hippocampus enhance the activity of ENTs. The study of the evoked release of ACh at different frequencies of stimulation allowed documenting a physiological situation where this A 2A receptor-mediated enhancement of ENTs activity plays a pivotal role in re-setting adenosine neuromodulation. Overall, these findings show a close interplay between adenosine production/inactivation and the activity of adenosine receptors to define adenosine neuromodulation.
